general banking issue, crypto legislation, Defense of CFPB, CRAs for overdraft, payments rule; stablecoin legislation.
FY 2025 appropriations, opposing policy riders in appropriations, budget reconciliations, opposition to budget resolution
Introduction Call - Rep. McIver, Rep Lieu re. access to justice, civil justice, Sen. Hickenlooper re. Product Safety.
H.R. 277, H.R. 357, H.R. H.R. 288, H.R. 890, H.R. 7528, H.R. 7533, H.R. 788, H.R. 3446, H.R. 115, H.R. 358, H.R. 7198, H.R. 7867, H.R. 8033, H.R. 9030, H.R. 9031, H.R. 9032, H.R. 9033, H.R. 9085. Regulatory reform, Stop Corporate Capture Act (H.R. 1507), Corner Post Reversal Act (H.R. 9014). Stop Corporate Capture Act (H.R. 1507, S. 4749), Comment Integrity and Management Act of 2024 (H.R. 7528). artificial intelligence safeguards, Blumenthal - product safety updates. REINS Act (H.R. 277). Green Tape Elimination Act.GOOD Act, Guidance Clarity Act, SOPRA, Stop Corporate Capture Act, Corner Post Reversal Act.
Direct File, financial transaction tax.
Reauthorize Office of Congressional Ethics (OCE), Communications with Congressional staff about corporate lobbying disclosure, DC statehood, prohibiting congressional stock trading activity, Regulating Inaugural funding, Freedom of Information Act reform, ETHICS Act (HR 2678, S 1171), Inaugural Fund Integrity Act (HR 535), Campaign Finance Disclosure Legislation, Met with House Member staff to discuss. DISCLOSE Act. Presidential Conflict of Interest Act. Discussion about Campaign Finance Disclosure Policy Ideas. Communications with House staff re: potential campaign disclosure legislation, Drafting memo to House encouraging Campaign Disclosure legislation; Communications with House staff re: potential campaign disclosure legislation.
H.R.3421 & S.1655 - Medicare for All, Health care nominations, Medicare Advantage
heat stress, OSHA issues.
anti-obesity medication pricing, Medicare drug price negotiation, international reference price negotiation price caps, number of drugs negotiated, out of pocket caps, inflation rebates, negotiation delay periods, direct-to-consumer pharmaceutical telehealth, Capping Prescription Costs Act, HHS Secretary, Deputy HHS Secretary, and CMS nominations, orphan drug exemption and negotiation delay period.H.R. 946 Orphan CURES Act; Medicare drug price negotiation eligibility delay period, S.652 Protecting Patients from Deceptive Drug Ads Online Act, EPIC Act (H.R. 1492 / S. 832), ORPHAN Cures Act (H.R.946), and MINI Act (H.R.1672); Medicare drug price negotiation delay periods and exemptions.
USPS issues